Day One Biopharmaceuticals, Inc.
- Jurisdiction
United States - ISIN
US23954D1090 (DAWN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Read full profile
Fundamentals
- Net revenue
€160.05M - Gross margin
94.0% - EBIT
-€95.31M - EBIT margin
-59.5% - Net income
-€81.03M - Net margin
-50.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
|
|
|
|
| Dubow Adam | Gen Counsel & Secretary |
|
|
|
|
| Merendino Lauren | Chief Commercial Officer |
|
|
|
|
| York Charles N II | COO and CFO |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |